BriaCell Therapeutics Corp.

BCTX | $2.19 -5.6% -5.94% 140K

(0.0% 1d) (1.8% 1m) (-61.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 34,999,980
https://www.briacell.com
Sec Filling | Patents | 2022 employees

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

cancer

add to watch list Paper trade email alert is off

Elevation Oncology Inc

ELEV | $4.03 -2.66% -2.73% 320K

Professional, Scientific, and T...

(0.0% 1d) (-0.2% 1m) (124.0% 1y) (0.0% 2d) (0.0% 3d) (-7.2% 7d) (29.15% volume)
Earnings Calendar: 2022-11-04
Market Cap: $ 196,063,993
https://elevationoncology.com
Sec Filling | Patents | 8 employees

Elevation Oncology is founded on the belief that every patient with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. The company makes genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. Together with its peers Elevation Oncology works towards a future in which each unique test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Its lead candidate, seribantumab, inhibits tumor growth driven by NRG1 fusions and is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion. Details on CRESTONE are available at www.NRG1fusion.com.

treatment cancer

add to watch list Paper trade email alert is off

Molecular Partners AG - ADR

MOLN | News | $3.67 -3.42% -3.54% 320

Professional, Scientific, and T...

(0.0% 1d) (1.0% 1m) (-37.2% 1y) (0.0% 2d) (0.0% 3d) (-1.0% 7d) (-51.97% volume)
Earnings Calendar:
Market Cap: $ 133,473,867
https://www.molecularpartners.com/
Sec Filling | Patents | 124 employees

(CH) brave bison is a social video company. we work with brands, creators and platforms to create, distribute and monetise video that’s fit for a digital world. we help to define brands’ needs in the content space to achieve actual business goals, helping them to crystallise why they should create social video in the first place and who to make it for. therefore how to execute it and how to distribute it in order to make a return on investment. we originate excellent branded content ideas that work in a digital world. culturally relevant ideas grounded in human insight and informed by data. real stories about real people; because we know that’s what garners engagement. content fit for purpose on ever-evolving digital platforms. there’s little point creating great video if no one’s watching it. so we distribute social video content; measuring, learning and acting on its performance. we work with brands to manage and distribute on owned channels to ensure that the best social video practice i

add to watch list Paper trade email alert is off

Werewolf Therapeutics Inc

HOWL | $5.87 0.51% 0.51% 120K

Professional, Scientific, and T...

(0.0% 1d) (-1.7% 1m) (136.4% 1y) (0.0% 2d) (4.1% 3d) (24.5% 7d) (-3.7% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 254,449,021
https://werewolftx.com
Sec Filling | Patents | n/a employees

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors.The company is continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

cancer immunotherapy msa treatment

add to watch list Paper trade email alert is off

Pyxis Oncology Inc

PYXS | $4.51 -6.63% -7.1% 470K

Professional, Scientific, and T...

(0.0% 1d) (-6.2% 1m) (50.5% 1y) (0.0% 2d) (3.0% 3d) (-1.8% 7d) (117.08% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 262,181,521
https://pyxisoncology.com
Sec Filling | Patents | 2021 employees

Pyxis Oncology, Inc. is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. Pyxis develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies.

cancer t-cell

add to watch list Paper trade email alert is off

Reneo Pharmaceuticals Inc

RPHM | $1.76 -0.57% -0.57% 76K

Professional, Scientific, and T...

(0.0% 1d) (7.3% 1m) (-80.2% 1y) (0.0% 2d) (7.3% 3d) (2.3% 7d) (616.69% volume)
Earnings Calendar: 2024-03-27
Market Cap: $ 58,820,622
https://reneopharma.com
Sec Filling | Patents | 32 employees

Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

energy renewable genetic metabolic

add to watch list Paper trade email alert is off

Sunshine Biopharma, Inc

SBFM | $3.315 -12.76% -14.63% 2.7M

Professional, Scientific, and T...

(0.0% 1d) (12263.6% 1m) (871.4% 1y) (0.0% 2d) (0.0% 3d) (8389.4% 7d) (-97.39% volume)
Earnings Calendar:
Market Cap: $ 329,686,247

Sec Filling | Patents | 3 employees

sunshine biopharma inc (sbfm) is a pharmaceuticals company based out of 469 jean-talon west, 3rd floor, montreal, québec, canada.

add to watch list Paper trade email alert is off

Definitive Healthcare Corp.

DH | $7.03 -2.23% -2.28% 410K

Professional, Scientific, and T...

(0.0% 1d) (-6.9% 1m) (-34.9% 1y) (0.0% 2d) (0.0% 3d) (-0.5% 7d) (468.56% volume)
Earnings Calendar: 2024-02-28
Market Cap: $ 828,057,971
https://www.definitivehc.com
Sec Filling | Patents | 2021 employees

Definitive Healthcare transforms data, analytics and expertise into healthcare commercial intelligence. The company helps clients uncover the right markets, opportunities and people, so they can shape tomorrow’s healthcare industry. Its SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next.

add to watch list Paper trade email alert is off

Vera Therapeutics Inc - Class A

VERA | $39.51 -1.25% -1.27% 860K

Professional, Scientific, and T...

(0.0% 1d) (-7.9% 1m) (513.7% 1y) (0.0% 2d) (-6.0% 3d) (-16.6% 7d) (-18.68% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 2,151,399,666

Sec Filling | Patents | 46 employees

trucode gene repair is advancing its novel triplex gene editing platform to potentially cure devastating genetic diseases, with initial focus on sickle cell disease and cystic fibrosis. the elegance of triplex gene editing lies in its ability to harness natural, high-fidelity dna repair mechanisms, and its independence from the requirement for exogenous nucleases and viral vectors.

t-cell

add to watch list Paper trade email alert is off

Connect Biopharma Holdings Ltd - ADR

CNTB | $1.51 -2.58% -2.65% 62K

Professional, Scientific, and T...

(0.0% 1d) (44.2% 1m) (61.7% 1y) (0.0% 2d) (0.0% 3d) (0.6% 7d) (35.2% volume)
Earnings Calendar:
Market Cap: $ 83,158,054
https://www.connectbiopharm.com
Sec Filling | Patents | 2021 employees

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from its T cell-driven research. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), which is a validated target for the treatment of several inflammatory diseases such as atopic dermatitis (AD) and asthma. Its second lead product candidate is CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1).

ceiling treatment brands antibody t-cell

add to watch list Paper trade email alert is off